Talphera (TLPH) Q3 2026 earnings review
Talphera raises its sales target, but trial recruiting slows down
Talphera's clinical trial for Niyad, its dialysis blood thinner, slowed down even as the company raised its long-term sales estimate. Chief executive Vince Angotti said patient recruiting slowed because hospitals had fewer qualifying intensive-care patients, leaving enrollment at "more than 75%" of the 70-patient goal — the same threshold reported three months ago. Meanwhile, quarterly operating costs excluding stock pay rose 18% from a year ago to $3.8 million, trimming cash to $14.2 million.
| NEPHRO trial enrollment | >75% of 70 75% last quarter; asking FDA to stop Dec 31 |
|---|---|
| Cash and investments | $14.2M down $2.9M from last quarter |
| Operating costs, excluding one-offs | $3.8M +18% from a year ago |
| Nafamostat peak sales estimate | >$200M raised on new doctor research |
⚖️ Verdict: 🔴 Bearish
The story got worse because activating all 14 hospital trial sites did not finish recruiting the 70 patients. Instead, the specialty drug maker asked the regulator for permission to stop enrollment on December 31 with fewer patients, lowering the trial's statistical power from over 90% to over 80%. On the positive side, new doctor surveys lifted management's peak sales estimate above $200 million, and an early stop would preserve the year-end timeline.
The question now is whether the Food and Drug Administration will let Talphera close the trial early and still file for approval. If the regulator agrees, top-line data arrives in early 2027 and can unlock conditional funding; if it demands all 70 patients, cash runs tight before the readout. The agency's Sprint Meeting feedback before December 31 will settle it.
🐂 Bull Case
Physician Research Lifts Peak Sales Estimate Above $200M
Talphera is developing Niyad, a freeze-dried version of the blood thinner nafamostat, to prevent blood clots in dialysis machines during continuous renal replacement therapy (CRRT) for intensive-care patients. Chief executive Vince Angotti said updated market research and doctor feedback support "an increased peak sales estimate of more than $200 million" for the product.
This builds on last quarter's research showing about 200,000 yearly US procedures and a billing code already in place. The drug developer also spent more on administrative costs this quarter for "pre-launch commercial preparation activities", showing it is preparing to sell the product to hospitals if the trial succeeds.
What to watch: the promised late-year investor presentation detailing the market research. Disclosing the assumed price per procedure and hospital adoption rate will show whether the $200 million target rests on realistic pricing.
FDA Precedent Could Preserve the Year-End Timeline
Rather than pushing its trial completion goal into 2027 after patient recruiting slowed, Talphera asked the Food and Drug Administration (FDA) for a fast-track Sprint Meeting. Angotti said the briefing document is "seeking feedback on closing enrollment as of December 31, 2026, even if fewer than the targeted 70 patients are enrolled".
Angotti noted that other CRRT trials struggled to recruit critically ill patients, and some sponsors stopped enrollment early and still won regulatory approval. Because Niyad holds Breakthrough Device Designation, a status that speeds up review for serious conditions, the agency has a formal process to consider the request quickly.
What to watch: the FDA's response from the Sprint Meeting before December 31, 2026. Agency agreement to accept the smaller patient count would allow the company to unblind the data in early 2027 without another timeline delay.
🐻 Bear Case
Enrollment Stalled and Talphera Wants to Stop Early
Last quarter, Talphera said all 14 hospital intensive-care sites were active and had enrolled 75% of the 70 patients needed for its NEPHRO registrational trial. Three months later, the wording has barely moved: the company still says it has enrolled "more than 75% of the planned 70 patients".
"Enrollment in the NEPHRO CRRT study has slowed over recent months, primarily due to fewer qualifying patients at our clinical sites," chief executive Vince Angotti said. That cuts against the prior view that activating the final hospital sites had solved the recruiting bottleneck. Instead of hitting the 70-patient goal by year-end, the pharmaceutical group wants to change the finish line to whatever count it has on December 31.
What to watch: the exact number of enrolled patients disclosed when the trial closes or in the quarterly filing. A count near 53 patients would mean the active hospital sites added almost no one during the third quarter.
Smaller Trial Sample Increases Binary Readout Risk
Niyad is Talphera's only active clinical program, so the company's future rests on the NEPHRO trial meeting its primary endpoint: measuring how long blood takes to clot in the dialysis filter over the first 24 hours compared with a placebo.
With the originally planned 70 patients, the trial had over 90% statistical power to detect whether the drug works. At the current patient count, Angotti said the study has "over 80% statistical power for the primary endpoint". Stopping early trades away roughly 10 percentage points of statistical cushion and leaves less data for secondary goals over 72 hours, such as filter lifespan and blood transfusions.
What to watch: top-line primary and 72-hour secondary endpoint results after enrollment closes. If the FDA allows an early stop but the smaller sample misses statistical significance, the company has no backup drug ready for trials.
Cash Drops to $14.2M as Trial Spend Rises
Talphera has no product sales and funds its operations from its balance sheet and milestone-tied financings. Cash and investments fell by $2.9 million during the quarter to $14.2 million, while quarterly operating expenses excluding stock pay rose 17.5% from a year ago to $3.8 million.
- Cash and investments: $14.2 million on September 30, down from $17.1 million on June 30
- Cash runway at the third-quarter spending pace: about 3.7 quarters by our math
- New filing planned: a Form S-3 shelf registration "to replace its existing Form S-3 that expires on November 30, 2026"
That leaves little room for regulatory delay, because roughly $16 million in remaining private-placement funding is tied to announcing the trial results. If the FDA refuses an early trial close, the extra months of spending will drain cash before those conditional funds unlock.
What to watch: fourth-quarter cash burn and the terms of the conditional financing tranches in the quarterly filing. Any delay in the trial readout past early 2027 would force the company to raise money under the new shelf registration.
Risks this quarter didn't answer
Three standing risks from earlier filings received no update in the third-quarter press release and depend on the upcoming quarterly report or conference call.
- Commercial pricing and hospital adoption: management raised the peak sales view above $200 million without stating the price per procedure or market share needed in the roughly 70 key hospitals.
- CorMedix negotiation rights and warrant overhang: the release gives no update on the 43.9 million outstanding warrants or how the board will manage partner CorMedix's 60-day exclusive acquisition negotiation window after trial data.
- China manufacturing and tariff exposure: Niyad finished goods rely on a contract manufacturer in China, and the release does not address backup supply or US pharmaceutical tariff costs.
💲 Other KPIs
Research and development spending rose 21.4% from a year ago and 29.5% from last quarter, reaching its highest level in five quarters. Talphera said the increase came from "increased Niyad development project activities" as it ran the clinical sites and prepared its regulatory briefing package.
Administrative and commercial preparation costs rose 20.2% from a year ago, though they stepped down 12.8% from the second quarter. The drug maker attributed the year-over-year rise to "pre-launch commercial preparation activities" and higher non-cash stock pay, which more than doubled to $220 thousand.
The average share count rose 82.2% from 41.5 million a year ago following last year's private-placement financings, though it was unchanged from the second quarter. That higher share count cut the reported loss per share from $0.11 to $0.05; excluding non-cash warrant revaluations, the net loss widened 19.7% by our math to $4.0 million.
🔮 Guidance
Cut. The specialty pharmaceutical group kept its year-end 2026 date to finish enrollment, but lowered what completion means by asking the FDA to let it close the study on December 31 with fewer than the planned 70 patients. This follows two earlier timeline delays from late 2025 and the first half of 2026.
❓ Key Questions
How many patients are enrolled right now?
Talphera reported 75% enrollment (~52–53 patients) in the second quarter and said "more than 75%" this quarter. Investors need the exact patient count to see how many patients joined after all 14 hospital sites became active.
What happens if the FDA rejects an early stop?
The company wants to close enrollment on December 31 with over 80% statistical power instead of the planned 90%. If the agency insists on all 70 patients, how many months will that add to the timeline and cash burn?
Do the conditional financing tranches require 70 patients?
Roughly $16 million in remaining financing is tied to the trial readout and share-price conditions. Management has not stated whether closing the trial below 70 patients requires a waiver from CorMedix and other investors.
What price and market share underpin the $200M estimate?
Talphera raised its nafamostat peak sales estimate above $200 million based on 200,000 yearly US procedures. Disclosing the assumed price per treatment and share in the 70 core hospitals would allow investors to test that figure.